Warning! GuruFocus detected
3 Severe warning signs
with UXI.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Cyclacel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US23254L4059
Description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 596.4 | |||||
| Equity-to-Asset | -0.18 | |||||
| Debt-to-Equity | -0.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -117.74 | |||||
| Beneish M-Score | -4.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12 | |||||
| 3-Year EPS without NRI Growth Rate | 20 | |||||
| 3-Year FCF Growth Rate | 17 | |||||
| 3-Year Book Growth Rate | -80.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 63.11 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 33.15 | |||||
| 14-Day RSI | 36.51 | |||||
| 6-1 Month Momentum % | -36.42 | |||||
| 12-1 Month Momentum % | -68.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.77 | |||||
| Quick Ratio | 0.77 | |||||
| Cash Ratio | 0.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.5 | |||||
| Shareholder Yield % | 0.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -20994.6 | |||||
| Net Margin % | -18150 | |||||
| FCF Margin % | -14201.47 | |||||
| ROE % | -2462.6 | |||||
| ROA % | -163.64 | |||||
| ROIC % | -971.44 | |||||
| 3-Year ROIIC % | 2879.82 | |||||
| ROC (Joel Greenblatt) % | -17731.74 | |||||
| ROCE % | -2732.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.16 | |||||
| EV-to-EBIT | -3.77 | |||||
| EV-to-EBITDA | -3.77 | |||||
| EV-to-Revenue | 791.59 | |||||
| EV-to-Forward-Revenue | 0.03 | |||||
| EV-to-FCF | -5.56 | |||||
| Earnings Yield (Greenblatt) % | -26.53 | |||||
| FCF Yield % | -17.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyclacel Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.068 | ||
| EPS (TTM) (€) | -8.632 | ||
| Beta | -1.39 | ||
| 3-Year Sharpe Ratio | -1.19 | ||
| 3-Year Sortino Ratio | -1.38 | ||
| Volatility % | 51.46 | ||
| 14-Day RSI | 36.51 | ||
| 14-Day ATR (€) | 0.00005 | ||
| 20-Day SMA (€) | 0.55 | ||
| 12-1 Month Momentum % | -68.75 | ||
| 52-Week Range (€) | 0.55 - 3.06 | ||
| Shares Outstanding (Mil) | 205.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyclacel Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyclacel Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cyclacel Pharmaceuticals Inc Frequently Asked Questions
What is Cyclacel Pharmaceuticals Inc(STU:UXI)'s stock price today?
The current price of STU:UXI is €0.55. The 52 week high of STU:UXI is €3.06 and 52 week low is €0.55.
When is next earnings date of Cyclacel Pharmaceuticals Inc(STU:UXI)?
The next earnings date of Cyclacel Pharmaceuticals Inc(STU:UXI) is 2025-04-02 Est..
Does Cyclacel Pharmaceuticals Inc(STU:UXI) pay dividends? If so, how much?
Cyclacel Pharmaceuticals Inc(STU:UXI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers